← Eichor
Condition: Resectable Esophageal Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Resectable Esophageal Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT07054086Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
Phase 2 · 3 location(s) · Zhejiang Cancer Hospital · NCT05507411A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT05182944DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07162506Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2 · 1 location(s) · Akeso · NCT07263919Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy fo
Phase 2 · 1 location(s) · The First Affiliated Hospital of Henan University of Science · NCT07622797Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Phase 3 · 1 location(s) · Henan Cancer Hospital · NCT04280822Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal
Phase 2 · 1 location(s) · Chuangzhen Chen · NCT07339488Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectabl
Phase 2 · 1 location(s) · Tongji University · NCT06304350Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT06663059The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Sq
Phase 3 · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT05547529Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06272214Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Phase 2 · 1 location(s) · Sichuan University · NCT06403878Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06354218A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal C
Phase 2 · 7 location(s) · VA Office of Research and Development · NCT05563766Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05327517Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06576973Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Guo Xufeng · NCT06056336A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N
Phase 1/Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07385001Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous C
Phase 2 · 1 location(s) · Tongji Hospital · NCT07699185Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Loc
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT07266493Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
NA · 2 location(s) · The First Affiliated Hospital of Henan University of Science · NCT02972372Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06385730Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005,
Phase N/A · 11 location(s) · Fudan University · NCT05443841Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06601309Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
Phase 2/Phase 3 · 1 location(s) · Shanghai Zhongshan Hospital · NCT04973306Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT05740995Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07457528Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1
Phase 3 · 1 location(s) · Henan Cancer Hospital · NCT04138212
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.